{"id":983158,"date":"2026-07-21T08:36:16","date_gmt":"2026-07-21T12:36:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/"},"modified":"2026-07-21T08:36:16","modified_gmt":"2026-07-21T12:36:16","slug":"maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/","title":{"rendered":"MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development"},"content":{"rendered":"<h2>\nTechnology License Partnership provides Genentech access to MaxCyte\u2019s portfolio of platform technologies across research, development, and manufacturing workflows<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>ROCKVILLE, Md., July  21, 2026  (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs.<\/p>\n<p>The license provides Genentech with access to MaxCyte\u2019s <em>ExPERT GTx<\/em><sup><strong><em>\u00ae<\/em><\/strong><\/sup> platform and additional platform technologies across select research, clinical development, and manufacturing workflows. Structured to support multiple programs, the license enables Genentech to support ex vivo applications for cell engineering.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>The capabilities across MaxCyte platform technologies are designed to streamline the advancement of cell therapy programs by providing integrated access to support cell engineering from early discovery to cGMP manufacturing. The partnership with Genentech underscores MaxCyte\u2019s expertise in enabling next-generation cell therapies by bringing together complementary technologies that support both cell engineering and analytical workflows across the development lifecycle.<\/p>\n<p>\u201cCell therapy development increasingly requires technology partners that can support programs as they advance from research through development and manufacturing,\u201d said Maher Masoud, President and CEO of MaxCyte. \u201cThis partnership allows MaxCyte to provide broader support to Genentech across the cell therapy lifecycle by bringing together complementary capabilities in cell engineering and gene editing. Through integrated access to these platforms, we are helping partners move forward with greater speed, confidence, and continuity.\u201d<\/p>\n<p>\n        <strong>About MaxCyte<\/strong>\n      <\/p>\n<p>At MaxCyte<sup>\u00ae<\/sup>, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation<sup>\u00ae<\/sup> technology and\u00a0SeQure\u2122 gene editing characterization assessment services\u00a0enable high-performance cell engineering and\u00a0rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we\u2019ve been advancing cell engineering, shaping the future of medicine.<\/p>\n<p>Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vs5eMx8g_pF2V4mqiba_sXhqtW_7c989bBdHD5dwkB0V9Cm3lTnMTYwNcfOwSepXpZDSpn_u78Xrm-TtrkbFGbRzgV3v9Zh1YeVEZVMC2xlOX6COzfcnEd0uY8xWIf56LohR28-P8gIqjminu15bf7uyyVJbyq9r3Qgjbu4njYGysCSJ_lz_M0L-DLSlzIriCX7RuCAKfqpR53xP7ftHsJRiRLTQgrJjbJNMKOlw3SpKYQe7gpc3S7j3qC7963e82FEXmM0hxlpEGlCqQtvX2GJleS6pWxagMfzbtSo7wap7TZMHrUchA1Pdpfi5s8WA3m82aPChSSxWPy8sbmTrtb-PAA7T_Hcg6E9mokCwrdcNt7T7pkBdzpoZgAqsXwYArBKJ24XdK4vabZWvYzw--YVAUVNIlDh9By1VPVijjjM=\" rel=\"nofollow\" target=\"_blank\">maxcyte.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V9RixkpTqvbbDCiRmC0FoKRCESdYv5rReK48jxkj24ahFUZQsE9eXYeVn2ADAyaxbHjfeoRB0KfLw_0HkeP6cHWS1ZPann_vvQJnNOIhMTHpZMzdCj7Ij04t6p90j3qlQs3bl8s2p_-EZxCTa1iHhnD3FYTsFcayzUkPktgtHUMFAnpaNupNVdqrFFjf7jvn-IgECm8kfkMJLZAA2jZD8XRxuH9LtjwgSXZnnt_ry98v9bruIWfsHZJZSra9hIacrST5BpnK77Ea0cwqA3Vf9RCphV_OR7DUrkQ8UjCeUsIQkCvSNEIi0n64FRXZMrWWDaGsvAL7m8e3nY1KtyuWEASY-Dn7cXt3blEFRjChxc1WOgxoI36Pbzj15QATTEXhf6Y0Jhq8cUCQN24Hv9tMhDEzsBYUyn5FV-Uf8EHm78_LD1Y7pSzcciV6XDVHUuTT\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CaSt3WmYbr8aN71KQ-KZIfq4MY2LYqUf-AIKtwgcZfbjeOEkBUW3YaS-7Rct91XLCGKTNjtq3AckugjDsXzmcZazigQ5YZTNoRMyV-0Zf2yF3MyB8_cao7bkNxZyXtw9LQh5zj2mkYzH5pvRrx7EVt4z5iBihFXrUjd07RDeqWrh5R8r2CScF5ZWKH3D-u6gzzzKcERvesWacyhz3OXylu502eJLXOvMrKDCUz5SP5J_4wfcBxIp4tTQtspuEX9sBh_7CQjP52M4IyTF5Ka54HIVkrIHQxuzGSzSLzSAczDVqbnBzfyXP7aaN6FA1J7m33VwnyoeOpmLcwNPQanHVl3wrvYOQz0MdbQByQX5p8kZLE8wi7I3YiplUQHpVJcDojmxAdHmNqJlsEyv6E1XTNuEubThbS64vP5-GqrgtQITOoKAvLwIlJhhpyKHDoHN\" rel=\"nofollow\" target=\"_blank\">Bluesky<\/a>.<\/p>\n<p>\n        <strong>MaxCyte Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>Gilmartin Group<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Erik Abdow<br \/>ir@maxcyte.com\u00a0\u00a0<\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>Oak Street Communications<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Kristen White<br \/>+1 415-608-6060<br \/>kristen@oakstreetcommunications.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgwOCM3NzEzNzUyIzIyMDUxNzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YzQ1MDNjMzItNzJkZS00NmMyLTliYjQtZGMxYmZlNGVjMDA4LTEyMTY3MzEtMjAyNi0wNy0yMS1lbg==\/tiny\/MaxCyte-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Technology License Partnership provides Genentech access to MaxCyte\u2019s portfolio of platform technologies across research, development, and manufacturing workflows ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs. The license provides Genentech with access to MaxCyte\u2019s ExPERT GTx\u00ae platform and additional platform technologies across select research, clinical development, and manufacturing workflows. Structured to support multiple programs, the license enables Genentech to support ex vivo applications for cell engineering.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The capabilities across MaxCyte &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-983158","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Technology License Partnership provides Genentech access to MaxCyte\u2019s portfolio of platform technologies across research, development, and manufacturing workflows ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs. The license provides Genentech with access to MaxCyte\u2019s ExPERT GTx\u00ae platform and additional platform technologies across select research, clinical development, and manufacturing workflows. Structured to support multiple programs, the license enables Genentech to support ex vivo applications for cell engineering.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The capabilities across MaxCyte &hellip; Continue reading &quot;MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-21T12:36:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgwOCM3NzEzNzUyIzIyMDUxNzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development\",\"datePublished\":\"2026-07-21T12:36:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\\\/\"},\"wordCount\":400,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NDgwOCM3NzEzNzUyIzIyMDUxNzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\\\/\",\"name\":\"MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NDgwOCM3NzEzNzUyIzIyMDUxNzg=\",\"datePublished\":\"2026-07-21T12:36:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NDgwOCM3NzEzNzUyIzIyMDUxNzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NDgwOCM3NzEzNzUyIzIyMDUxNzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/","og_locale":"en_US","og_type":"article","og_title":"MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development - Market Newsdesk","og_description":"Technology License Partnership provides Genentech access to MaxCyte\u2019s portfolio of platform technologies across research, development, and manufacturing workflows ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs. The license provides Genentech with access to MaxCyte\u2019s ExPERT GTx\u00ae platform and additional platform technologies across select research, clinical development, and manufacturing workflows. Structured to support multiple programs, the license enables Genentech to support ex vivo applications for cell engineering.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The capabilities across MaxCyte &hellip; Continue reading \"MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-21T12:36:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgwOCM3NzEzNzUyIzIyMDUxNzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development","datePublished":"2026-07-21T12:36:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/"},"wordCount":400,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgwOCM3NzEzNzUyIzIyMDUxNzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/","name":"MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgwOCM3NzEzNzUyIzIyMDUxNzg=","datePublished":"2026-07-21T12:36:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgwOCM3NzEzNzUyIzIyMDUxNzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDgwOCM3NzEzNzUyIzIyMDUxNzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-announces-multi-platform-technology-license-partnership-with-genentech-to-advance-cell-therapy-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MaxCyte\u00ae Announces Multi-Platform Technology License Partnership with Genentech\u00ae to Advance Cell Therapy Development"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/983158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=983158"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/983158\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=983158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=983158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=983158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}